Handal Brian, Enlow Rossanna, Lara Daniel, Bailey Mark, Vega Francisco, Hu Peter, Lennon Alan
Molecular Genetic Technology Program, School of Health Professions, University of Texas-M.D. Anderson Cancer Center, Houston, TX.
Department of Hematopathology.
J Assoc Genet Technol. 2013;39(1):14-20.
Diffuse Large B-cell Lymphoma (DLBCL) is the most common form of lymphoma, accounting for 40 percent of newly diagnosed cases each year. DLBCL is an aggressive abnormal growth of tissue characterized by the accumulation of abnormal B-lymphocytes in the lymphatics of affected individuals. The goal of this study was to analyze microRNA (miRNA) as an alternative method of diagnosis and treatment for patients affected with the observed cancer. MiRNAs are small, non-coding, endogenous RNA that control gene expression at the post-transcriptional level. Emerging evidence suggests that miRNA-mediated gene regulation has a functional role in cancer and could prove to be crucial targets for therapeutic intervention. Here, we provide a quantitative study on the expression of a diverse class of oncogenic and tumor suppressive miRNA that have shown to regulate oncoproteins involved in differentiation, proliferation, and/or apoptosis.
